national association social workers coming serious heat group members letter opposition group october national association social workers nasw sent specialty practice sections mental health private practice emailed invitation join national adherence initiative schizophrenia article november issue nasw news also announces describes initiative brief text email asked social workers consider enrolling nationwide data collection effort stated partial adherence significant problem treatment schizophrenia affect patients invited participants identify clients schizophrenia feel risk partial adherence last line text informed initiative sponsored janssen l p partnership nasw pharmaceutical company janssen subsidiary johnson johnson markets risperdal risperidone antipsychotic drug grossed billion sales social workers enrolled received packet janssen study instrument spoke nothing importance drug treatment adherence schizophrenia say oh gets even juicy treatment compliance old issue schizophrenia care everyone field knows antipsychotic drugs unpleasant effects make extremely undesirable patients janssen initiative closely follows government sponsored catie studies findings three quarters patients atypical antipsychotics janssen risperdal falsely touted decade vast improvements older drugs stop taking prescribed medication inefficacy intolerable adverse effects reasons study instrument mailed social workers consists eight yes questions describing deficit patients would put risk partial adherence view information already well known dozens previous studies adherence neuroleptic treatment including million catie studies nearly patients likely come janssen nasw study adherence initiative repeats partial adherence significant problem treatment schizophrenia significant problem lies rather drugs well established ineffectiveness adverse effects would janssen pay close attention janssen exclusive patent market oral risperidone expire company stands lose significant revenue cheaper generic versions come market janssen therefore emphasizing long acting injectable version risperidone markets risperdal consta still holds patent several years sells oral version history antipsychotic drug use shows one notion one notion ever justified using long acting injectable antipsychotics adherence compliance light must janssen adherence initiative fully appreciated appears janssen initiated contact nasw matter allegedly made contribution nasw foundation return collaboration janssen going information i know i speculate wanted get patients try janssen product like risperdal consta invega new antipsychotic essentially clone risperdal i know next steps hopefully social workers respect patient confidentiality start handing names contact information researchers summarize janssen gets wild hair contacts nasw agrees participate research campaign help patients possibly exchange donation janssen little scientific knowledge gained study janssen gets push risperdal consta invega could large group patients unfortunately i able track full text email i work i follow story develops thanks writhe safely covering story note site offended notably profanity